Back to Search
MICHAEL CHER, MD
MD
Urology Physician
NPI: 1336187400IndividualAccepts Medicare
Education
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Class of 1986
Research & Publications (20)
Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section.
PMID 16651608·Am J Pathol·2006
8-other
Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.
PMID 12788977·Proc Natl Acad Sci U S A·2003
7-preclinical
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
PMID 19447430·J Urol·2009
3-trial
Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis?
PMID 18769612·Curr Oncol·2008
8-other
C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis.
PMID 18714401·Neoplasia·2008
7-preclinical
Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
PMID 18472961·Neoplasia·2008
7-preclinical
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells.
PMID 18403754·Stem Cells·2008
8-other
CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.
PMID 18337451·Mol Cancer Res·2008
8-other
Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner.
PMID 18324629·Int J Cancer·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4100 JOHN R ST
DETROIT, MI 48201 - Phone
- (800) 527-6266
Quick Facts
- NPI
- 1336187400
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 40
- Publications
- 20
Are you this provider?
Claim Your Profile